Pharmafile Logo

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol…

Read the full article: https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Infographic: Spondyloarthritis

Overview of spondyloarthritis patient profiles and treatment pathways.

Webinar: Demand assessment – Reflecting real world choices

How study design which reflects doctors’ real world choices can optimise results.

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Competition from within

Published in eyeforpharma July 29 by Rachel Howard

Infographic: RA Perceptions

HCPs predict the future of the biologics market

From chaos to calm: how to make sense of social media

What do you know about chaos theory?

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

Infographic: HCV LATAM

An introduction to the HCV LATAM patient.

Spotlight on Saudi Arabia

Published in eyeforpharma 20 May by Rachel Howard